In September, several leadership changes were announced across the ophthalmic space.
Foventa Therapeutics appointed Dr. Zaiba Malik as chief medical officer and Julia Jones as chief financial officer, according to a press release.
CEO Olav Hellebø was recently appointed as CEO, and the team is aiming to secure Series A funding to bring FOV407 into a phase 2b trial. FOV407 is under investigation as a topical therapy for diabetic retinopathy.
Samsara Vision announced Jason Herod has been promoted to president and CEO.
He most recently served as chief commercial officer and was responsible for